Clinical Trial Data Repressed

A new study finds that important drug safety data are not seeing the light of day.

By | January 5, 2012


Data from early stage clinical trials are not being widely reported, thus putting patients at risk, according to a handful of new studies in the British Medical Journal. The missing data includes both safety and efficacy findings that go unreported or are published in obscure places. "This is no academic matter, because missing data about harm in trials can harm patients, and incomplete data about benefit can lead to futile costs to health systems," wrote Oxford University researcher Richard Lehman and BMJ editor Elizabeth Loder in an editorial accompanying the studies. "Moreover, researchers or others who deliberately conceal trial results have breached their ethical duty to trial participants."

These deficiencies surface even after the US Food and Drug Administration enacted rules in 2007 to mandate the posting of all clinical trial data on within 12 months of the studies' conclusions.

In one of the BMJ studies, researchers found that only 22 percent of trials registered on in 2009 had results available a year after being completed. And fewer than half of all National Institutes of Health-funded trials are published in a peer-reviewed journal within 30 months of completion, another study reported.

"When the word 'mandatory' turns out to mandate so little," Lehman and Loder wrote, "the need for stronger mechanisms of enforcement becomes very clear."


Add a Comment

Avatar of: You



Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. Birth of the Skin Microbiome
    Daily News Birth of the Skin Microbiome

    The immune system tolerates the colonization of commensal bacteria on the skin with the aid of regulatory T cells during the first few weeks of life, a mouse study shows.

  2. Inside a Lab Mouse’s High-Fat Diet
  3. Battling the Bulge
    Bio Business Battling the Bulge

    Weight-loss drugs that target newly characterized obesity-related receptors and pathways could finally offer truly effective fat control.

  4. How Gastric Bypass Can Kill Sugar Cravings
Life Technologies